乳酸杆菌与双歧杆菌对高脂血症治疗的相关性研究

Correlation of Lactobacillus and Bifidobacterium treatment for hyperlipidemia

  • 摘要: 目的 分析高脂血症患者临床治疗效果与补充肠道乳酸杆菌、双歧杆菌的相关性。 方法 对2012年3月- 2014年6月于我院就诊的120例高脂血症患者男性85例,女性35例,年龄(48.1±11.6)岁随机分为4组:A组低脂饮食+运动,B组给予降血脂药物,C组给予肠道菌群调节剂,D组给予降血脂药物+肠道菌群调节剂治疗,疗程为1个月。所有患者于入院前、治疗1个月、3个月时进行血脂、肠道菌群检测。 结果 治疗前、治疗1个月、3个月血脂水平:C组总胆固醇(total cholesterol,TC)(mmol/L)6.69±1.29、6.18±1.04、6.78±1.14;三酰甘油(triglyceride,TG)(mmol/L):1.91±0.32、1.87±0.46、1.93±0.28;高密度脂蛋白胆固醇(high density lipoprotein cholesterol,HDL-C)(mmol/L):0.91±0.35、0.97±0.33、0.97±0.36;D组TC:6.79±1.39、4.11±1.07、4.27±1.03;TG:1.90±0.55、1.36±0.41、1.39±0.29;HDL-C:0.88±0.30、1.32±0.39、1.24±0.35。C组降血脂效果最差(1个月:30%;3个月:16.7%),D组降血脂效果最好(1个月:76.6%;3个月:70%)。随时间变化HDL-C水平在C组存在回升和反弹现象(治疗前:0.88±0.30;1个月:1.32±0.39;3个月:0.97±0.36)。C组治疗1个月时乳酸杆菌和双歧杆菌(logn/g)(7.49±0.34,9.50±0.15)显著高于治疗前(6.85±0.26,9.32±0.12)、治疗3个月(6.73±0.28,9.22±0.14)后;而D组治疗1个月(7.63±0.62,9.55±0.14)、3个月(7.42±0.59,9.51±0.11)时乳酸杆菌和双歧杆菌均显著高于治疗前(6.88±0.23,9.27±0.13)。 结论 乳酸杆菌、双歧杆菌干预可能对高脂血症患者临床疗效起到积极作用。

     

    Abstract: Objective To investigate the correlation between clinical outcomes in patients with hyperlipidemia and the distribution of Lactobacillus and Bifidobacterium. Methods From March 2012 to June 2014, 120 cases with hyperlipidemia (85 males, 35 females, average age of (48.1±11.6) years) in our hospital were randomly divided into four groups, and they were provided with one-month treatment. Group A were treated with low fat diet + exercise; group B were treated with lipid-lowering drug therapy; group C were treated with intestinal flora regulator treatment; group D were treated with lipid-lowering drugs + modulators. The serum lipids and intestinal flora detections were given in all patients separately before admission, 1 month after treatment, and 3 months after treatment. The lipid levels of patients in four groups, the changes of intestinal microflora and the blood lipid sustainment after treatment in different periods were analyzed and compared. Results The total cholesterol (TC) of group C before treatment, 1 month and 3 months after treatment was (6.69±1.29) mmol/L, (6.18±1.04) mmol/L and (6.78±1.14) mmol/L, triglyceride (TG) was (1.91±0.32) mmol/L, (1.87±0.46) mmol/L, (1.93±0.28) mmol/L; high density lipoprotein cholesterol (HDL-C) was (0.91±0.35) mmol/L, (0.97±0.33) mmol/L, (0.97±0.36) mmol/L; while TC in group D was (6.79±1.39) mmol/L, (4.11±1.07) mmol/L, (4.27±1.03) mmol/L, TG: (1.90±0.55) mmol/L, (1.36±0.41) mmol/L, (1.39±0.29) mmol/L, HDL-C: (0.88±0.30) mmol/L, (1.32±0.39) mmol/L, (1.24±0.35) mmol/L. The effect of lowering blood lipid in group C was the worst (1 month 30%; 3 months 16.7%), in group D was the best (1 month 76.6%; 3 months 70%). There was rebound phenomenon of HDL-C level in group D as time changed HDL-C: before treatment (0.88±0.30) mmol/L, 1 month (1.32±0.39) mmol/L, 3 months (0.97±0.36) mmol/L. The Lactobacillus and Bifidobacteria in group C at 1 month after treatment was significantly higher than before treatment and three months after treatment (7.49±0.34) vs (6.85±0.26), (6.73±0.28); (9.50±0.15) vs (9.32±0.12), (9.22±0.14), and Lactobacillus and Bifidobacteria in group D at 1 month and 3 months after treatment was significantly higher than before treatment (7.63±0.62), (7.42±0.59) vs (6.88±0.23); (9.55±0.14), (9.51±0.11) vs (9.27±0.13). Conclusion Lactobacillus and Bifidobacteriumintervention treatment has positive therapeutic effect in patients with hyperlipidemia.

     

/

返回文章
返回